Avatar photo

Dr. Vlad Ratziu

Vlad Ratziu, MD, PhD is professor of hepatology at the Sorbonne Université and the Hôpital Pitié-Salpêtrière Medical School in Paris, France since 2004.

NASH 2024: The New Nomenclature and Revised Definition

Dive into the transformative world of liver health with Prof. Vlad Ratziu's enlightening insights on the latest nomenclature and definitions for steatotic liver disease. Discover why the medical community is adopting a new, inclusive language for Non-Alcoholic Fatty Liver Disease (NAFLD), now redefined to reflect its complex interplay with metabolic dysfunction and lifestyle factors.
Read MoreNASH 2024: The New Nomenclature and Revised Definition
Dr. Vlad Ratziu - France

Fibrosis vs. steatohepatitis in NASH: key prognostic and regulatory implications

Fibrosis is an independent predictor of liver-related mortality but rarely if ever occurs without NASH as NASH is the progressive form of the disease and drives fibrosis progression. This means the question arises on whether anti-fibrotic drugs are better than anti-NASH drugs and vice versa which Dr. Vlad Ratziu explores in this video.
Read MoreFibrosis vs. steatohepatitis in NASH: key prognostic and regulatory implications
Vlad Ratziu, MD, PhD, is a Professor of Hepatology at Sorbonne University and Pitié-Salpêtrière Hospital in Paris, France. His main research interests are in the field of NAFLD; the mechanisms, risk factors, and progression of liver fibrosis in viral and metabolic diseases; and the treatment of viral hepatitis and hepatocellular carcinoma. He has participated in early, mid, and late-stage trials of NASH and has published more than 260 articles in prominent journals.
Prof. Ratziu coordinated the Fatty Liver Inhibition of Progression (FLIP) consortium, which sought to study both the mechanisms of liver disease progression in NAFLD and potential interventions, drawing on the largest cohort of NAFLD patients in Europe. He is co-editor for the Journal of Hepatology.